Antioxidants: Do they have a place in the prevention or therapy of acute kidney injury?

Nephron - Experimental Nephrology

Volumn 109, Issue 4, 2008, Pages

  Koyner, Jay L ^a   Sher Ali, Roshan ^b   Murray, Patrick T ^a,c  

^a UNIVERSITY OF CHICAGO   (United States)

^b ROCHESTER GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Acute kidney injury; Anti oxidants; Free radicals; Oxidative stress; Reactive oxygen metabolites

Indexed keywords

ACETYLCYSTEINE; ALKADIENE; ALLOPURINOL; ALPHA TOCOPHEROL; AMIFOSTINE; ANTIOXIDANT; ASCORBIC ACID; BICARBONATE; CARNITINE; CISPLATIN; DIMETHYLTHIOUREA; EBSELEN; FERRITIN; FREE RADICAL; GENTAMICIN; GLUTATHIONE; HEME; HEME OXYGENASE 1; HYDROGEN PEROXIDE; KALLIKREIN; KININ; MALONALDEHYDE; MANNITOL; MYOGLOBIN; PLACEBO; POLYPHENOL; REACTIVE OXYGEN METABOLITE; SILYMARIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UNINDEXED DRUG;

AORTA SURGERY; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; HEARING LOSS; HEART SURGERY; HUMAN; KIDNEY INJURY; LIPID PEROXIDATION; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SEPSIS;

ANIMALS; ANTIOXIDANTS; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY BYPASS; GENTAMICINS; HUMANS; KIDNEY FAILURE, ACUTE; OXIDATIVE STRESS; RHABDOMYOLYSIS; SEPSIS;

EID: 52449093542     PISSN: 16602129     EISSN: None     Source Type: Journal    
DOI: 10.1159/000142935     Document Type: Review

References (59)

1. Shah SV, Baliga R, Rajapurkar M, et al: Oxidants in chronic kidney disease. J Am Soc Nephrol 2007;18:16-28.
2. Fridovich I: The biology of oxygen radicals. Science 1978;201:875-880.
3. Halliwell B, Gutteridge J: Role of free radicals and catalytic metal ions in human disease: an overview. Meth Enzymol 1990;186:1-85.
4. Siegel NJ, Devarajan P: Pathogenesis of acute renal failure;in Avner HW, Niaudet P (eds): Pediatric Nephrology, ed 5. Philadelphia, Lippincott Williams & Wilkins, 2004, pp 1223-1232.
5. Swaminathan S, Shah SV: Novel approaches targeted toward oxidative stress for the treatment of chronic kidney disease. Curr Opin Nephrol Hypertens 2008;17:143-148.
6. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, et al: Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol 2006;26:287-292.
7. Mishra J, Dent C, Tarabishi R, et al: Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005;365:1231-1238.
8. Mishra J, Mori K, Ma Q, et al: Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for Cisplatin nephrotoxicity. Am J Nephrol 2004;24:307-315.
9. Parikh CR, Jani A, Mishra J, et al: Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am J Transplant 2006;6:1639-1645.
10. Schmidt-Ott KM, Mori K, Li JY, et al: Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2007;18:407-413.
11. Hearse DJ, Humphrey SM, Bullock GR: The oxygen paradox and the calcium paradox: two facets of the same problem? J Mol Cell Cardiol 1978;10:641-668.
12. Chertow G, Levy E, Hammermeister K, et al: Independent association between acute renal failure and mortality following cardiac surgery. Am J Med 1998;104:343-348.
13. Sucu N, Cinel I, Unlu A, et al: N-acetylcysteine for preventing pump-induced oxidoinflammatory response during cardiopulmonary bypass. Surg Today 2004;34:237-242.
14. Haase M, Haase-Fielitz A, Bagshaw SM, et al: Phase II, randomized, controlled trial of high-dose N-acetylcysteine in high-risk cardiac surgery patients. Crit Care Med 2007;35:1324-1331.
15. Hoffmann U, Fischereder M, Kruger B, et al: The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004;15:407-410.
16. Haase M, Haase-Fielitz A, Ratnaike S, et al: N-acetylcysteine does not artifactually lower plasma creatinine concentration. Nephrol Dial Transplant 2008;17:17.
17. Lassnigg A, Punz A, Barker R, et al: Influence of intravenous vitamin E supplementation in cardiac surgery on oxidative stress: a double-blinded, randomized, controlled study. Br J Anaesth 2003;90:148-154.
18. Larsen M, Webb G, Kennington S, et al: Mannitol in cardioplegia as an oxygen free radical scavenger measured by malondialdehyde. Perfusion 2002;17:51-55.
19. Burns KE, Chu MW, Novick RJ, et al: Perioperative N-acetylcysteine to prevent renal dysfunction in high-risk patients undergoing cabg surgery: a randomized controlled trial. JAMA 2005;294:342-350.
20. Ristikankare A, Kuitunen T, Kuitunen A, et al: Lack of renoprotective effect of i.v. N-acetylcysteine in patients with chronic renal failure undergoing cardiac surgery. Br J Anaesth 2006;97:611-616.
21. El-Hamamsy I, Stevens LM, Carrier M, et al: Effect of intravenous N-acetylcysteine on outcomes after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial. J Thorac Cardiovasc Surg 2007;133:7-12.
22. Hynninen MS, Niemi TT, PöyhiäR, et al: N-acetylcysteine for the prevention of kidney injury in abdominal aortic surgery: a randomized, double-blind, placebo-controlled trial. Anesth Analg 2006;102:1638-1645.
23. Macedo E, Abdulkader R, Castro I, et al: Lack of protection of N-acetylcysteine (NAC) in acute renal failure related to elective aortic aneurysm repair: a randomized controlled trial. Nephrol Dial Transplant 2006:21:1863-1869.
24. Moore NN, Lapsley M, Norden AG, et al: Does N-acetylcysteine prevent contrast-induced nephropathy during endovascular AAA repair? A randomized controlled pilot study. J Endovasc Ther 2006;13:660-666.
25. Wijnen MH, Roumen RM, Vader HL, et al: A multiantioxidant supplementation reduces damage from ischaemia reperfusion in patients after lower torso ischaemia: a randomised trial. Eur J Vasc Endovasc Surg 2002;23:486-490.
26. Salom MG, Ceron SN, Rodriguez F, et al: Heme oxygenase-1 induction improves ischemic renal failure: role of nitric oxide and peroxynitrite. Am J Physiol Heart Circ Physiol 2007;293:H3542-H3549.
27. Akagi R, Takahashi T, Sassa S: Fundamental role of heme oxygenase in the protection against ischemic acute renal failure. Jpn J Pharmacol 2002;88:127-132.
28. Starkopf J, Zilmer K, Vihalemm T, et al: Time course of oxidative stress during open-heart surgery. Scand J Thorac Cardiovasc Surg 1995;29:181-186.
29. Himmelfarb J, McMonagle E, Freedman S, et al: Oxidative stress is increased in critically ill patients with acute renal failure. J Am Soc Nephrol 2004;15:2449-2456.
30. Perianayagam MC, Liangos O, Kolyada AY, et al: NADPH oxidase p22phox and catalase gene variants are associated with biomarkers of oxidative stress and adverse outcomes in acute renal failure. J Am Soc Nephrol 2007; 18:255-263.
31. Santos NA, Catao CS, Martins NM, et al: Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch Toxicol 2007;81:495-504.
32. Ajith TA, Usha S, Nivitha V: Ascorbic acid and alpha-tocopherol protect anticancer drug cisplatin induced nephrotoxicity in mice: a comparative study. Clin Chim Acta 2007;375:82-86.
33. Lynch ED, Gu R, Pierce C, et al: Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen. Hear Res 2005;201:81-89.
34. Baliga R, Zhang Z, Baliga M, et al: In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int 1998;53:394-401.
35. Satoh M, Kashihara N, Fujimoto S, et al: A novel free radical scavenger, edarabone, protects against cisplatin-induced acute renal damage in vitro and in vivo. J Pharmacol Exp Ther 2003;305:1183-1190.
36. Iguchi T, Nishikawa M, Chang B, et al: Edaravone inhibits acute renal injury and cyst formation in cisplatin-treated rat kidney. Free Radic Res 2004;38:333-341.
37. Hishida A: Clinical analysis of 207 patients who developed renal disorders during or after treatment with edaravone reported during post-marketing surveillance. Clin Exp Nephrol 2007;11:292-296.
38. Capizzi RL: Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects. Semin Oncol 1999;26(2 suppl 7):72-81.
39. Humes HD: Aminoglycoside nephrotoxicity. Kidney Int 1988;33:900-911.
40. Walker P, Barri Y, Shah S: Oxidant mechanisms in gentamicin nephrotoxicity. Renal Failure 1999;21:433-442.
41. Zurovsky Y, Haber C: Antioxidants attenuate endotoxin-gentamicin induced acute renal failure in rats. Scand J Urol Nephrol 1995; 29:147-154.
42. Kopple JD, Ding H, Letoha A, et al: L-Carnitine ameliorates gentamicin-induced renal injury in rats. Nephrol Dial Transplant 2002; 17:2122-2131.
43. Bledsoe G, Crickman S, Mao J, et al: Kallikrein/ kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis. Nephrol Dial Transplant 2006;21:624-633.
44. Varzi HN, Esmailzadeh S, Morovvati H, et al: Effect of silymarin and vitamin E on gentamicin-induced nephrotoxicity in dogs. J Vet Pharmacol Ther 2007;30:477-481.
45. Kuhad A, Tirkey N, Pilkhwal S, et al: Effect of Spirulina, a blue green algae, on gentamicin-induced oxidative stress and renal dysfunction in rats. Fundam Clin Pharmacol 2006;20:121-128.
46. Dhanarajan R, Abraham P, Isaac B: Protective effect of Ebselen, a selenoorganic drug, against gentamicin-induced renal damage in rats. Basic Clin Pharmacol Toxicol 2006;99: 267-272.
47. Feldman L, Efrati S, Eviatar E, et al: Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. Kidney Int 2007;72:359-363.
48. Mazzon E, Britti D, De Sarro A, et al: Effect of N-acetylcysteine on gentamicin-mediated nephropathy in rats. Eur J Pharmacol 2001; 424:75-83.
49. Mostafa BE, Tawfik S, Hefnawi NG, et al: The role of deferoxamine in the prevention of gentamicin ototoxicity: a histological and audiological study in guinea pigs. Acta Otolaryngol 2007;127:234-239.
50. Baliga R, Ueda N, Walker PD, et al: Oxidant mechanisms in toxic acute renal failure. Am J Kidney Dis 1997;29:465-477.
51. Aydogdu N, Atmaca G, Yalcin O, et al: Protective effects of L-carnitine on myoglobinuric acute renal failure in rats. Clin Exp Pharmacol Physiol 2006;33:119-124.
52. Rodrigo R, Bosco C, Herrera P, et al: Amelioration of myoglobinuric renal damage in rats by chronic exposure to flavonol-rich red wine. Nephrol Dial Transplant 2004;19:2237-2244.
53. Merten GJ, Burgess WP, Gray LV, et al: Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004;291:2328-2334.
54. Bouzas-Mosquera A, Recio-Mayoral A: Sodium bicarbonate, N-acetylcysteine, and saline for the prevention of contrast-induced nephropathy. Am Heart J 2008;155:e31.
55. Stadtman ER, Berlett BS, Chock PB: Manganese-dependent disproportionation of hydrogen peroxide in bicarbonate buffer. Proc Natl Acad Sci USA 1990;87:384-388.
56. Zager RA: Rhabdomyolysis and myohemoglobinuric acute renal failure. Kidney Int 1996;49:314-326.
57. Ozguc H, Kahveci N, Akkose S, et al: Effects of different resuscitation fluids on tissue blood flow and oxidant injury in experimental rhabdomyolysis. Crit Care Med 2005;33: 2579-2586.
58. Brown CV, Rhee P, Chan L, et al: Preventing renal failure in patients with rhabdomyolysis: do bicarbonate and mannitol make a difference? J Trauma 2004;56:1191-1196.
59. Nath KA, Balla G, Vercellotti GM, et al: Induction of heme oxygenase is a rapid, protective response in rhabdomyolysis in the rat. J Clin Invest 1992;90:267-270.